🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you Ashish M. Kamat, MD, MBBS for leading a great tumor board and Urology Times for the opportunity to have this conversation! Huntsman Cancer Institute YUO Bladder Cancer Advocacy Network

Congrats Naomi Haas and team for the 5 yr update on ph3 Keynote-564 in #kidneycancer 👉 Ab#4514 ASCO #ASCO25 👉bit.ly/44KiA7o👉Benefits w/ adjuvant pembro over placebo maintained (DFS HR 0.71 & OS HR 0.66)👇Toni Choueiri, MD Tom Powles OncoAlert UroToday.com KidneyCAN

Congrats Tian Zhang, MD, MHS and Toni Choueiri, MD Alliance for Clinical Trials in Oncology for A031704/PDIGREE step 1 results and the years it took, persistence and trial design with patient support ! Largest RCC trial in the NCTN to date!

Exciting to see initial results from step 1 of PDIGREE by Tian Zhang, MD, MHS lower CR rate than expected and a meaningful subset did not make it to step 2. This remains a study that we’ll all await the primary results from as it could impact practice #ASCO25

A consistent DFS difference over time (now a long time) clearly shows activity and likely increased cure and not just delay (as with S-TRAC). Still effect size is modest. Need better molecular diagnostic tests for patient selection and likely combos in (neo)adj. ❤️ this progress

EV-P is the right treatment. It’s time to learn how to really use it. #JacquelineBrown said. Wonderful discussion of novel strategies in 1L metastatic urothelial cancer. ASCO #FeaturedVoices OncoAlert SEOM Oncology Brothers

Amazing discussion. Worth listening to 1) understand mUC in 2025-2026 and 2) learn strategies for how to deliver a compelling discussion. Well done!

🌟Great presentation by Chadi Hage Chehade at #ASCO25!! Utilization and timing of NGS in pts w/ 5 most common cancers in the US👉Many pts either don’t receive NGS or have the first NGS very late 👇ASCO OncoAlert Neeraj Agarwal, MD, FASCO Umang Swami Flatiron Health UroToday.com

Come tomorrow morning to hall B1 at 8am for a great discussion of RCC management. Lots to discuss including adjuvant tx, irAE management and more! Worked with a great group to develop a fantastic program thanks to ASCO, Jodie Maranchie, Catherine Fahey, and Scott Capozza

Grateful for the opportunity to participate in the upcoming Ph3 trial! Great opportunity for patients.

👉🏻 Our very own Chadi Hage Chehade presenting ASCO a real-world study showing most patients do not undergo NGS testing, and a substantial proportion receive it only near end of life—limiting its clinical utility and impact on treatment decisions. #ASCO25 GU Cancer Research Program @HuntsmanCancer Neeraj Agarwal, MD, FASCO

🧬 From Localized to Metastatic: Navigating RCC Treatment Join us as experts walk through real-world cases across the RCC continuum—from adjuvant therapy to mRCC. 💡 Risk stratification, treatment decisions & biomarkers in focus. 📍 #ASCO25 | Benjamin L Maughan Scott Capozza, PT, MSPT

🧪Exciting science in GU - Kidney & Bladder at #ASCO25! Don’t miss these cutting-edge posters on: ✅Novel immuno + targeted combos ✅OxPhos metabolism ✅QOL & real-world data ✅CAR T-cell therapy in ccRCC Featuring work lisaderosa Alex Chehrazi-Raffle, MD Benjamin L Maughan Shilpa Gupta Sumanta K. Pal, MD, FASCO ..

👉🏻 Superstar Zeynep Irem Ozay, MD presenting ASCO our real-world data showing lutetium has better survival outcomes than cabazitaxel in post-ARPI/docetaxel mCRPC patients. #ASCO25 ASCO #ProstateCancer GU Cancer Research Program @HuntsmanCancer Neeraj Agarwal, MD, FASCO OncoAlert UroToday.com

The #IRONMAN registry with some practical updates on PSA response in metastatic hormone sensitive #prostatecancer — depth of PSA response matters — sets up current #TRIPLESWITCH trial in CCTG SWOG Cancer Research Network. Congrats Michael Ong & team. #ASCO25 UroToday.com

📢#ASCO25 AttardLab presented AMPLITUDE, a Phase 3 RCT of Niraparib + AAP vs PBO + AAP in HRR-mutated mCSPC 🧬 HRRm: rPFS ↓ 37% (HR 0.63; p=0.0001) 🧬 BRCA: rPFS ↓ 48% (HR 0.52; p<0.0001), symptomatic progression ↓ 56% ⏳ OS trend in BRCA (HR 0.75) – not yet mature ⚠️ AEs:

Chicago in June is beautiful and we were happy to be there for #ASCO25. Impressed with the clinicians, researchers, advocates, and all those raising their voices to support #cancerresearch, #kidneycancer, and progress on behalf of patients! Already looking forward to next year!

Nicolas Sayegh, MD Zeynep Irem Ozay, MD ASCO GU Cancer Research Program @HuntsmanCancer Neeraj Agarwal, MD, FASCO OncoAlert UroToday.com Umang Swami Georges Gebrael Geoff Oxnard MD Nazli Dizman Benjamin L Maughan Huntsman Cancer Institute Sumanta K. Pal, MD, FASCO Shilpa Gupta SOUMYAJIT ROY Irbaz Riaz MD,MS,MBI,PhD We would like to inform you that your post has been published on OncoDaily.com. Thank you for sharing. oncodaily.com/insight/zeynep…

Excited to attend this meeting. Stellar faculty and superb program. Will be a fun time!!

Just in Clinical Cancer Research 👉Congrats Chadi Hage Chehade Umang Swami & GU Cancer Research Program @HuntsmanCancer team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 Flatiron Health Foundation Medicine Ryon Graf, PhD 👉 need to add PARPi 👉free link: bit.ly/3TsOw9i OncoAlert UroToday.com